Randomized, Double-Blind Phase III study of Pazopanib vs Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Trial Profile

Randomized, Double-Blind Phase III study of Pazopanib vs Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2013

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2013 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center: CTSU-E2810).
    • 05 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top